Hepatitis B immune globulin and HBV-related liver transplantation

  title={Hepatitis B immune globulin and HBV-related liver transplantation},
  author={Sinan Akay and Zeki Karasu},
  journal={Expert Opinion on Biological Therapy},
  pages={1815 - 1822}
Post-transplant hepatitis B virus (HBV) recurrence prophylaxis is a sine qua non of liver transplantation for HBV-related liver disease because of high rate and aggressive course of HBV recurrence. Hepatitis B immune globulin (HBIG) is a polyclonal immune globulin solution obtained from plasma, donated by individuals with high titres of anti-HBs (hepatits B antibody). Although it was being used for postexposure prophylaxis against HBV since 1974, its use in post-transplant propyhlaxis of HBV… Expand
3 Citations
Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents
  • M. Labro
  • Biology, Medicine
  • Expert review of anti-infective therapy
  • 2012
The first part of this review focuses on the potential immunomodulating properties of anti-infective agents, beginning with antibacterial and antiviral agents. Expand
Virology and vaccines


Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
At a median follow-up of 1.1 years, combination prophylaxis with lamivudine and HBIG prevented hepatitis B recurrence following liver transplantation. Expand
Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization.
Patients transplanted for chronic HBV cirrhosis show no evidence of recurrent HBV, and pharmacokinetic analysis of anti-Hbs elimination can improve immunoglobulin therapy and prevent recurrence of clinical hepatitis. Expand
Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin.
When failure of prophylaxis with lamivudine and HBIG occurs, adefovir dipivoxil should be considered to be a safe and effective choice for recurrent HBV infections in liver transplant patients. Expand
Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation
Results suggest that lamivudine administered after a posttransplantation course of HBIG can effectively prevent the recurrence of HBV infection in patients who are HBsAg positive and HBeAg negative before OLT. Expand
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation
The data suggest that in selected liver transplant recipients, posttransplantation HBV vaccination may be a useful and cost‐effective strategy in the prophylaxis of HBV recurrence, allowing the discontinuation of life‐long HBIG treatment. Expand
Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
Substitution of HBIg with lamivudine is effective for prevention of HBV recurrence in low-risk liver transplant recipients and offers a convenient and cost-effective alternative for long-term HBV prophylaxis. Expand
Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin.
  • E. Yoshida, S. Erb, +5 authors U. Steinbrecher
  • Medicine
  • Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 1999
It is suggested that combination lamivudine and low-dose HBIG is effective in preventing allograft reinfection by HBV. Expand
Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization.
High-dose HBIg prevented HBV infection of the allograft in 29 of 32 patients transplanted for HBV cirrhosis with three non-HBV associated deaths, and serum mercury levels remained below standards for industrial exposure, and only one individual developed post-transplant HCV infection after receiving multiple units of unscreened blood prior to 1991. Expand
Liver transplantation in European patients with the hepatitis B surface antigen.
In this retrospective study of HBsAg-positive patients, liver transplantation had better results in those who had fulminant hepatitis or delta virus superinfection and reduced mortality. Expand
Low-Dose Hepatitis B Immune Globulin and Higher-Dose Lamivudine Combination to Prevent Hepatitis B Virus Recurrence after Liver Transplantation
A combination of lamivudine 300 mg/day and low-dose HBIG prevents post-trans transplantation recurrence of hepatitis B, even in the presence of viral replication in the pre-transplant period. Expand